Zipalertinib posts brain activity data in EGFR-mutated lung cancer trial
Taiho Oncology and Cullinan Therapeutics reported results from Cohort C of the Phase 2b REZILIENT2 study of zipalertinib in EGFR-mutated non-small cell lung cancer with active central nervous system metastases. The cohort included 59 enrolled patients and had a median follow-up of 9.2 months; the median intracranial response duration was 9.7 months. The findings are scheduled for presentation on October 26, 2026, at the ESMO Congress.
Why it matters
Zipalertinib remains an investigational treatment and has not been approved by a health authority, so the report does not change its regulatory status. The October 26 presentation will provide a formal venue for reviewing the trial data.
Key facts
- 1Cohort C had enrolled 59 patients at the data cutoff, with median follow-up of 9.2 months. investing.com
- 2The median intracranial duration of response was 9.7 months among the evaluable patients. investing.com
- 3Patients received zipalertinib at a dose of 100 mg twice daily. investing.com
- 4The trial findings are scheduled for presentation on October 26, 2026. stocktitan.net
Open questions
- The materials report different intracranial objective response rates for the 43 evaluable patients: 67.4% in material 1 and 30.2% in material 2.
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.